Summarized by Masters of Longevity from Sofinnova Partners.
A single-arm trial began to test weekly sutacimig prophylaxis in ~75 GT patients.
Key Takeaways
- The trial is single-arm with intra-participant run-in comparison.
- Phase 2 data showed reduced treated bleed rates but was nonrandomized.
- Three Grade 2 thromboembolic events were reported in higher‑exposure cohorts.
